Diisopropylphosphorofluoridate-induced muscle hyperactivity associated with enhanced lipid peroxidation in vivo

Laskowski, 1977, The pharmacology of experimental myopathies, Annu Rev Pharmacol Toxicol, 17, 387, 10.1146/annurev.pa.17.040177.002131

Laskowski, 1975, Ultrastructural changes at the motor endplate produced by an irreversible cholinesterase inhibitor, Exp Neurol, 47, 290, 10.1016/0014-4886(75)90258-7

Wecker, 1978, Relationship between acetylcholinesterase inhibtion and the development of a myopathy, J Pharmacol Exp Ther, 206, 97

Misulis, 1987, Differences in central and peripheral neural actions between soman and diisopropyl fluorophosphate, organophosphorus inhibitors of acetylcholinesterase, Toxicol Appl Pharmacol, 89, 391, 10.1016/0041-008X(87)90158-X

Clinton, 1988, Effects of phenytoin, ketamine, and atropine methylnitrate in preventing neuromuscular toxicity of acetylcholinesterase inhibitors soman and diisopropylphosphorofluoridate, J Toxicol Environ Health, 24, 439, 10.1080/15287398809531175

Wecker, 1977, Effects of denervation on the production of an experimental myopathy, Exp Neurol, 57, 94, 10.1016/0014-4886(77)90047-4

Patterson, 1988, Prevention of diisopropylphosphorofluoridate (DFP)-induced skeletal muscle fiber lesions in rat, Toxicology, 48, 237, 10.1016/0300-483X(88)90104-7

Sket, 1991, Prevention of diisopropylphosphorofluoridate-induced myopathy by botulinum toxin type A blockage of quantal release of acetylcholine, Acta Neuropathol (Berl), 82, 134, 10.1007/BF00293956

Yang ZP and Dettbarn W-D, Diisopropylphosphorofluoridate induced cholinergic hyperactivity and lipid peroxidation. Toxicol Appl Pharmacol, in press.

Gupta, 1987, Alterations of high-energy phosphate compounds in the skeletal muscles of rats intoxicated with diisopropylphosphorofluoridate (DFP) and soman, Fund Appl Toxicol, 8, 400, 10.1016/0272-0590(87)90089-3

Sjodin, 1990, Biochemical mechanisms for oxygen free radical formation during exercise, Sports Med, 10, 236, 10.2165/00007256-199010040-00003

Yang, 1995, Increases in malondialdehyde-thiobarbituric acid complex (MDA-TBA) and F2-isoprostanes (PGF2) in diisopropyl fluorophosphate (DFP) induced muscle hyperactivity, FASEB J, 9, A694

Morrow, 1992, Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids, 89, 10721

Sinnhuber, 1957, 2-Thiobarbituric acid method for the measurement of rancidity in fishery products: II. The quantitative determination of malondialdehyde, Food Technol, 12, 9

Largilliere, 1988, Free malondialdehyde determination in human plasma by high-performance liquid chromatography, Anal. Biochem., 170, 123, 10.1016/0003-2697(88)90098-X

Draper, 1990, Malondialdehyde determination as index of lipid peroxidation, Methods Enzymol, 186, 421, 10.1016/0076-6879(90)86135-I

Draper, 1993, A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials, Free Radic Biol Med, 15, 353, 10.1016/0891-5849(93)90035-S

Braughler, 1989, The 21-aminosteroids: Potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia, Drugs Future, 14, 143, 10.1358/dof.1989.014.02.101095

Hall, 1991, U-78517F: A potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia, J Pharmacol Exp Ther, 258, 688

Longmire, 1994, Effect of oxygen tension on the generation of F2-isoprostanes and malondialdehyde in peroxidizing rat liver microsomes, Biochem Pharmacol, 47, 1173, 10.1016/0006-2952(94)90389-1

Hartman, 1986, Succinylcholine: Mechanisms of fasciculations and their prevention by d-tubocurarine or diphenylhydantoin, Anesthesiology, 65, 405, 10.1097/00000542-198610000-00010